|Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023|
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.
The hybrid conference will be held from Oct. 11-15 at the Boston Convention and Exhibition Center. Access the full schedule here. All IDWeek abstracts are embargoed until Oct. 11 at 8:00 a.m. ET.
Title: Early Experience with Omadacycline for the Treatment of Diabetic Foot Infections*
Title: A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects*
Title: Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015-2022)
Title: High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019-2021)
Other Paratek Events at IDWeek 2023
Paratek invites attendees to visit the company's onsite Booth #1024 from Oct. 11-15 and to participate in the following events:
About Paratek Pharmaceuticals, Inc.
The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development of omadacycline for pulmonary anthrax and the U.S.-based commercial manufacturing of NUZYRA.
|10/5/2023 8:00:00 AM